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RESEARCH ARTICLE Open Access
MRI-detected brain lesions in AF patients
without further stroke risk factors
undergoing ablation - a retrospective
analysis of prospective studies
Juliane Herm1†, Johannes Schurig1†, Martin R. Martinek3, Reinhard Höltgen4, Alexander Schirdewan5ˆ,
Paulus Kirchhof6, Marcus Wieczorek4,7, Helmut Pürerfellner3, Peter U. Heuschmann8,9,10, Jochen B. Fiebach2 and
Karl Georg Haeusler11*
Abstract
Background: Atrial fibrillation (AF) without other stroke risk factors is assumed to have a low annual stroke risk
comparable to patients without AF. Therefore, current clinical guidelines do not recommend oral anticoagulation
for stroke prevention of AF in patients without stroke risk factors. We analyzed brain magnetic resonance imaging
(MRI) imaging to estimate the rate of clinically inapparent (“silent”) ischemic brain lesions in these patients.
Methods: We pooled individual patient-level data from three prospective studies comprising stroke-free patients
with symptomatic AF. All study patients underwent brain MRI within 24–48 h before planned left atrial catheter
ablation. MRIs were analyzed by a neuroradiologist blinded to clinical data.
Results: In total, 175 patients (median age 60 (IQR 54–67) years, 32% female, median CHA2DS2-VASc = 1 (IQR 0–2),
33% persistent AF) were included. In AF patients without or with at least one stroke risk factor, at least one silent
ischemic brain lesion was observed in 4 (8%) out of 48 and 10 (8%) out of 127 patients, respectively (p > 0.99).
Presence of silent ischemic brain lesions was related to age (p = 0.03) but not to AF pattern (p = 0.77). At least one
cerebral microbleed was detected in 5 (13%) out of 30 AF patients without stroke risk factors and 25 (25%) out of
108 AF patients with stroke risk factors (p = 0.2). Presence of cerebral microbleeds was related to male sex (p = 0.04)
or peripheral artery occlusive disease (p = 0.03).
Conclusion: In patients with symptomatic AF scheduled for ablation, brain MRI detected silent ischemic brain
lesions in approximately one in 12 patients, and microbleeds in one in 5 patients. The prevalence of silent ischemic
brain lesions did not differ in AF patients with or without further stroke risk factors.
Keywords: Clinically silent stroke - atrial fibrillation - magnetic resonance imaging - cerebral microbleeds
Background
Atrial fibrillation (AF) is the most common cardiac
arrhythmia worldwide causing about 15–20% of all ische-
mic strokes. Individual stroke risk is determined by the
presence of cardiovascular risk factors such as arterial
hypertension, old age and prior stroke [1]. About 3.5% of
all AF patients do not have coexisting cardiovascular risk
factors (“lone” AF) [2]. Based on a reported thrombo-
embolic event rate of 0.4–0.8% per year, AF without stroke
risk factors is considered to be a “benign” disease [3, 4]
and oral anticoagulation is not recommended in these pa-
tients for secondary stroke prevention [1]. According to
an observational study, the prevalence of fibrotic changes
in the left atrium – which is linked to stroke risk [5] – was
reported to be similar in AF patients with and without
coexisting cardiovascular risk factors [6] but reported
findings are inconsistent [7].
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Brain magnetic resonance imaging (MRI) may help to
better quantify the stroke risk of AF patients without
stroke risk factors by assessing clinically “silent” ische-
mic brain lesions, known to be related to clinical evident
stroke [8, 9] and dementia [10, 11]. In addition, MRI
quantifies the microangiopathic lesion load - so called
“white matter hyperintensities” - an established marker
of small-vessel disease and linked to AF-related cerebral
hypoperfusion, endothelial dysfunction or embolism to
the brain [12, 13]. Moreover, brain MRI is capable to de-
tect small hypointense T2*-lesions (so called “cerebral
microbleeds”), a known risk factor for microangiopathic
disease and intracerebral hemorrhage [14, 15].
In order to analyze whether silent ischemic brain le-
sions are found more frequently in AF patients with at
least one stroke risk factor compared to those without
stroke risk factors, we retrospectively analyzed individual
patient data assessed in three prospective monocenter
studies focusing on MRI-detected brain lesions after left
atrial catheter ablation for symptomatic AF in Germany
or Austria [16, 17]. Furthermore, we compared the fre-
quency of cerebral microbleeds or white matter hyperin-
tensities (WMH) in AF patients with or without stroke
risk factors.
Methods
Study design and study population
According to the respective study protocols, all three
studies recruited consecutive patients presenting for pul-
monary vein isolation in symptomatic AF. Patients were
eligible for the present analysis if they had symptomatic
non-permanent AF and no history of prior stroke or
transient ischemic attack (TIA). Focusing on silent brain
lesions after ablation, all patients underwent “baseline”
brain MRI within 24–48 h prior to scheduled ablation.
All patients underwent echocardiography according to
study protocols in order to rule out a thrombus before
ablation. Left atrial dimensions were determined in 165
(94.3%) patients using the parasternal view in 81% and
the apical 4-chamber view in 19%. A dilated left atrium
was therefore defined as ≥42mm in diameter (paraster-
nal view) or ≥ 58 mm (long axis, apical view) [18, 19]. In
all three studies, demographic data including stroke risk
factors were assessed.
The present data pooling has been approved by the Eth-
ics Committee of the Charité –Universitätsmedizin Berlin,
Germany (EA4/087/08). Furthermore, each individual
study was approved by the local Ethics Committee before
(Ethics Committee Witten/Herdecke, Germany (114/
2016); Ethics Committee of the Elisabethinen University
Teaching Hospital Linz, Austria (K-103-16)). Individual
patient data were taken from the MACPAF study (n = 35;
[16]), the Austrian study (n = 116; [17]) and a study in
Bocholt, Germany (n = 24).
Brain imaging
Using a 3 Tesla MR scanner (Siemens, Erlangen,
Germany) in Berlin; Germany [16] and a 1.5 Tesla MR
scanner (Siemens, Erlangen, Germany) in Linz, Austria
and Bocholt, Germany, the following MRI sequences were
assessed in 175 study patients: diffusion-weighted mag-
netic resonance imaging (DWI; n = 175) to identify acute
ischemic brain lesions; T2*-weighted imaging (n = 138) to
diagnose microbleeds and exclude brain hemorrhage, and
Fluid-attenuated inverse recovery (FLAIR, n = 58) or con-
ventional T2 weighted images (n = 117) to assess the mi-
croangiopathic load. Evaluation of all MRI images was
done by a board certified neuroradiologist (JBF), blinded
to all clinical data White matter hyperintensities (WMH)
were graded according to the Fazekas score [20]. A cere-
bral microbleed was defined as a small (≤10mm), hypoin-
tense lesion in T2*-weighted imaging. The nomenclature
endorsed by STRIVE was used as applicable [21]. To allow
a comparison of reported brain MRI data to patients with-
out AF, a subgroup of volunteers enrolled to the prospect-
ive single-center “Berlin Beat of Running study” [22] was
analyzed. An identical MRI protocol was used in the
“Berlin Beat of Running study” and in the MACPAF study.
Statistical analysis
Absolute and relative frequencies were reported for cat-
egorical variables. As a result of comparably small sample
sizes, normal distribution of continuous variables could
not be assumed. Therefore, medians and quartiles were
calculated for all variables. The Fisher exact test was used
to compare proportions of dichotomous outcomes be-
tween independent groups. The Mann-Whitney test was
used to compare proportions of nominal variables be-
tween independent groups. Impact factors regarding the
burden of cerebral microbleeds were reported using a
Poisson regression model. A p < 0.05 indicates significant
associations.
Results
Baseline data of all 175 study patients are shown in Table 1.
Median age at enrolment was 60 (IQR 54–67) years, 32%
of all patients were female. Median CHA2DS2-VASc-score
was 1.0 (IQR 0.0–2.0, range 0–5). Overall, 48 (27%) patients
presented without further stroke risk factors (defined as a
CHA2DS2-VASc-score = 0 in men (n = 38) or = 1 in women
(n = 10)). Comparing patients across studies, patients re-
cruited in Bocholt, Germany had more frequently congest-
ive heart failure compared to MACPAF patients enrolled in
Berlin, Germany (21% vs. 2%, p = 0.04) or patients enrolled
in Linz, Austria (21% vs. 6%, p = 0.02), respectively. More-
over, all MACPAF patients had paroxysmal AF (defined in-
clusion criterion), whereas 61% of all patients enrolled in
Linz, Austria and 50% of all patients enrolled in Bocholt
presented with paroxysmal AF (p < 0.001). Age, sex and
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further cardiovascular risk factors did not differ across stud-
ies (see Additional file 1).
MRI-detected ischemic brain lesions
Brain MRI before planned ablation detected acute (n =
2) or chronic (n = 12) silent ischemic brain lesions in 14
(8%) patients without a history of stroke (Fig. 1). Silent
ischemic brain lesions were classified as territorial
stroke (n = 7) or small subcortical singular lesions with-
out surrounding white matter disease (n = 6) or with
surrounding white matter disease (“lacunes of pre-
sumed vascular origin”; n = 1). In AF patients, silent is-
chemic lesions were observed in 4 (8%) out of 48 AF
patients without stroke risk factors compared to 10 out
of 127 (8%) AF patients with at least one stroke risk
factor (p > 0.99). (Table 2). The median CHA2DS2-VASc--
score did not differ in patients with and without
MRI-detected silent ischemic brain lesions (p = 0.43). In
more detail, 3 (5%) out of 58 patients with a CHA2DS2--
VASc score of 1 (excluding female sex), 3 (8%) out of 40 pa-
tients with a CHA2DS2-VASc score of 2 (excluding female
sex) and 4 (14%) of 29 patients with a CHA2DS2-VASc
score of ≥3 (excluding female sex) had MRI-detected silent
ischemic brain lesions. Old age was associated with the
presence of ischemic lesions (p = 0.03), while individual
stroke risk factor(s) such as diabetes and arterial hyperten-
sion as well as sex, AF type or left atrial diameter were not
(Table 2).
Table 1 Baseline characteristics of 175 study patients with AF but without known ischemic stroke
All study AF without stroke risk factors
patients
n = 175
No
(n = 48)
Yes
(n = 127)
p*
Age; years, median (IQR) 60.0
(54.0–67.0)
56.5
(49.3–60.8)
64.0
(55.0–67-0)
–
Female sex; n (%) 56 (32.0) 10 (20.8) 46 (36.2) –
Congestive heart failure; n (%) 14 (8.0) – 14 (11.0) –
Arterial hypertension; n (%) 100 (57.1) – 100 (78.7) –
Diabetes mellitus; n (%) 17 (9.7) – 17 (13.4) –
Peripheral artery occlusive disease; n (%) 4 (2.3) – 4 (3.1) –
Coronary artery disease; n (%) 33 (18.9) – 33 (26.0) –
Cardiomyopathy; n (%) 9 (6.0) 2 (4.5) 7 (6.5) > 0.999
Hyperlipoproteinemia; n (%) 87 (49.7) 18 (37.5) 69 (54.3) 0.062
Dilated left atrium; n (%) 75 (45.5) 14 (31.8) 61 (50.4 0.036
Paroxysmal AF 118 (67.4) 36 (75.0) 82 (64.6) 0.210
Fig. 1 a Conventional T2-weighted imaging showing a single ischemic brain lesion in a female AF patient aged 63 years without stroke risk
factors and (b) Fluid-attenuated inverse recovery (FLAIR) showing a single ischemic brain lesion in a male AF patient aged 50 years without stroke
risk factors
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To compare our cohort of 48 AF patients without
stroke risk factors to a healthy population without AF,
we identified an age- and sex-matched subgroup of the
“Berlin Beat of Running study”, enrolling (non-profes-
sional) healthy endurance athletes aged 35 to 60 years
before running a marathon. In 37 volunteers (median 54
years, range 39–60 year; 22% female), 3 T MRI identified
no silent ischemic lesions (0% vs. 8% in AF patients
without stroke risk factors (median 57 years, range 27–
64 years; 21% female); p = 0.129)).
MRI-detected white matter hyperintensities (WMH)
WMH were found in 81 (46%) of all 175 study patients
and in 19 (40%) of 48 AF patients without stroke risk
factors. The Fazekas score was equally distributed in AF
patients with or without stroke risk factor(s) (median 0.0
(IQR 0.0–1.0, range 0–2) vs. median 0.0 (IQR 0.0–1.0,
range 0–2; p = 0.26). The Fazekas score was higher in
patients with MRI-detected cerebral microbleeds com-
pared to patients without cerebral microbleeds (median
1.0 (IQR 0.0–1.0) vs. 0.0 (IQR 0.0–1.0); p = 0.01) as well
Table 2 Cardiovascular risk profile of study patients with and without MRI-detected silent ischemic lesions
Silent ischemic brain lesions
No
(n = 161)
Yes
(n = 14)
p-value*
≥1 stroke risk factor** No 44 (27.3) 4 (28.6) > 0.999
Yes 137 (72.7) 10 (71.4)
Age; median (IQR) 60 (54–66) 67 (61–69) 0.026
Female sex; n (%) 50 (31.1) 6 (42.9) 0.318
Congestive heart failure; n (%) 11 (6.8) 1 (7.1) > 0.999
Arterial hypertension; n (%) 94 (58.4) 6 (42.9) 0.275
Diabetes mellitus; n (%) 15 (9.3) 2 (14.5) 0.630
Vascular disease; n (%) 34 (21.1) 1 (7.1) 0.307
Hyperlipoproteinemia; n (%) 77 (47.8) 10 (71.4) 0.103
Paroxysmal AF; n (%) 109 (67.7) 9 (64.3) 0.773
Dilated left atrium; n (%) 70 (45.8) 5 (41.7) > 0.999
Left ventricular ejection fraction < 50%; n (%) 11 (7.0) 0 (0) > 0.999
* p-value calculated by chi2-test or Mann-Whitney U test, as appropriate. ** According to CHA2DS2-VASc-score (“No” equals 0 in men and 1 in women, “Yes” equals
≥1 in men and ≥ 2 in women)
Table 3 Cardiovascular risk profile of patients with or without white matter hyperintensities (WMH) according to brain MRI
WMH*
No
(n = 94)
Yes
(n = 81)
p-value**
≥1 stroke risk factor*** No 29 (30.9) 19 (23.5) 0.310
Yes 65 (69.1) 62 (76.5)
Age; median (IQR) 58 (52–64) 64 (57–69) < 0.001
Female sex; n (%) 29 (30.9) 27 (33.3) 0.747
Congestive heart failure; n (%) 6 (6.4) 6 (7.4) > 0.999
Arterial hypertension; n (%) 53 (56.4) 47 (58.0) 0.879
Diabetes mellitus; n (%) 8 (8.5) 9 (11.1) 0.615
Peripheral artery occlusive disease; n (%) 2 (2.1) 2 (2.5) > 0.999
Coronary artery occlusive disease; n (%) 15 (16.0) 18 (22.2) 0.335
Hyperlipoproteinemia; n (%) 43 (45.7) 44 (54.3) 0.290
Paroxysmal AF; n (%) 57 (60.6) 61 (75.3) 0.052
Dilated left atrium according to echocardiography; n (%) 39 (43.8) 36 (47.4) 0.754
Left ventricular ejection fraction < 50%; n (%) 5 (5.4) 6 (7.6) 0.756
* WMH were determined according to Fazekas score. ** p-value calculated by chi2-test or Mann-Whitney U test, as appropriate. *** According to CHA2DS2-VASc-score
(“No” equals 0 in men and 1 in women, “Yes” equals ≥ 1 in men and ≥ 2 in women)
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as in patients with MRI-detected ischemic lesions com-
pared to those without (median 1.0 (IQR 0.8–1.0) vs. 0.0
(IQR 0.0–1.0); p = 0.02). Old age (p < 0.01) was associ-
ated with MRI-detected WMH, while other individual
stroke risk factors such as arterial hypertension, diabetes
as well as sex were not (Table 3).
MRI-detected cerebral microbleeds
T2*-weighted imaging was performed in 138 (79%) out of
all 175 study patients. Comparing patients with
T2*-weighted imaging to those without, the prevalence of
stroke risk factors and the distribution of age and sex did
not differ. Compared to those patients without
T2*-weighted imaging, patients with T2*-weighted im-
aging more often had persistent AF (41% vs. 3%, p < 0.01).
All 138 patients received oral anticoagulation (using phen-
procoumon (n = 122) or a non-vitamin-K dependent oral
anticoagulant (n = 16)) for at least six weeks prior to abla-
tion according to the local study protocol [17]. Brain MRI
detected at least one cerebral microbleed in 30 (22%)
patients, 6 (4%) had more than one cerebral microbleed
(median 1.0 (IQR 1.0–1.0, range 1–4)) (Fig. 2, Table 4).
Location of supratentorial cerebral microbleeds was
strictly lobar in 23 (77%) patients, strictly deep in 3 (9%)
patients and mixed in 1 (3%) patient (Table 5). In AF pa-
tients without stroke risk factors, cerebral microbleeds
were observed in 5 (13%) out of 39 compared to 25 (25%)
out of 99 in AF patients with stroke risk factors (p = 0.17).
There was a statistical non-significant trend towards a
lower burden of cerebral microbleeds in AF patients with-
out stroke risk factors (median 0.0 (IQR 0.0–0.0) vs. me-
dian 0.0 (IQR 0.0–1.0) in AF patients with stroke risk
factors (p = 0.09)). Male sex (p = 0.04) and peripheral
artery occlusive disease (p = 0.03) were associated with the
presence of MRI-detected cerebral microbleeds, while dia-
betes, arterial hypertension, AF pattern and age were not.
Using a Poisson regression model, male sex (OR 4.3
(95%CI 1.4–12.6)) and patients age (OR 1.8 per decade
(95%CI 1.1–2.7)) were associated with a higher burden of
cerebral microbleeds, while diabetes, arterial hypertension,
peripheral artery occlusive disease, coronary artery disease
or congestive heart failure were not (data not shown).
Discussion
The main finding of this retrospective analysis of
patient-level data assessed within three prospective mono-
center studies is that the prevalence of MRI-detected
silent ischemic brain lesions as well as the burden of cere-
bral microangiopathy is similar in AF patients with or
without stroke risk factors. The burden of cerebral micro-
bleeds was comparably low in AF patients without stroke
risk factors, which was not reported before.
According to guideline recommendations, the clinical
impact of MRI-detected silent ischemic brain lesions in
AF patients is low [1]. However, a MRI-based cohort
study including 400 AF patients demonstrated an ele-
vated risk for later ischemic stroke in patients with
MRI-detected silent ischemic brain lesions [23]. There-
fore, one might argue that MRI-detected silent ischemic
brain lesions should have similar implications as a tran-
sient ischemic attack (TIA) diagnosed on clinical
grounds alone. While published cohort studies and a
meta-analysis on brain MRI findings in unselected AF
patients reported a prevalence of silent ischemic brain
lesions of 28–90% [24–26], a cohort study including 38
AF patients with a CHA2DS2-VASc-score of 0 reported
MRI-detected silent ischemic brain lesions in 3% in
these patients [23]. We observed at least one silent is-
chemic brain lesion in 8% of all 175 patients, similarly
distributed in AF patients with (8%) or without at least
one stroke risk factor (8%, p > 0.99). Of note, silent is-
chemic brain lesions were either territorial strokes or
small subcortical singular lesions, thus indicating pre-
dominantly embolic sources as previously discussed in
AF patients [25]. Of note, comparing our cohort of 48
AF patients without stroke risk factors to 37 age- and
sex-matched individuals without stroke risk factors, a
subgroup of the prospective “Berlin Beat of Running
study”, 3 T MRI identified no silent ischemic lesions.
However, as the “Berlin Beat of Running Study” had en-
rolled only marathon participants aged 35–60 years, we
Fig. 2 T2*-weighted imaging depicting multiple cerebral
microbleeds (indicated by arrows) in a man aged 71 years with
known AF and coronary artery occlusive
disease (CHA2DS2-VASc-score = 2)
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cannot draw definitive conclusions regarding the preva-
lence of silent ischemic brain lesions in non-AF patients
over 60 years of age.
Focusing on white matter lesions, a low microangio-
pathic lesion load was present in the entire study cohort,
which is in line with the observed cardiovascular risk
profile (Table 1). However, at least a single microangio-
pathic brain lesion was found in in 46% of all 175
AF-patients without prior stroke. Not focusing AF
patients without stroke risk factors, a cohort study re-
ported white matter lesions in 68% of 74 AF patients
(median Fazekas 1, median CHA2DS2-VASc-score 2, me-
dian age 59 years) without prior stroke or TIA planned
for left atrial catheter ablation [27]. As the prevalence of
peripheral artery occlusive disease and diabetes was
considerably lower in our cohort than in this Polish
population, this may account for the lower number of
patients with white matter lesions. Comparing AF pa-
tients with or without stroke risk factors, the Fazekas
score was equally distributed in our cohort (median 0
(IQR 0–1) vs. median 0 (IQR 0–1), p = 0.26).
A recent meta-analysis demonstrated a 4-fold in-
creased risk of future intracerebral hemorrhage in AF
patients with ischemic stroke and MRI-detected cerebral
microbleeds [28]. In AF patients with clinically evident
ischemic stroke, at least one cerebral microbleed has
been reported in 22–49% of patients [29, 30]. We
observed at least one cerebral microbleed in 13% of AF
patients without stroke risk factors and in 25% of AF pa-
tients with stroke risk factors (p = 0.17; Table 4). There
was a non-significant trend towards a higher burden of
cerebral microbleeds if present in AF patients with
stroke risk factors compared to those without (p = 0.09).
Study patients with a higher burden of cerebral micro-
bleeds were more often male and older compared to
study patients without cerebral microbleeds.
Our study has several limitations. First, this is a retro-
spective analysis of individual patient data acquired in
prospective studies with a slightly different MRI proto-
col- using 1.5 Tesla (n = 140) or 3 Tesla (n = 35) which
may impact on the detection of acute ischemic lesions
[31]. Unfortunately, a sensitivity analysis is not applic-
able due to the limited number of patients undergoing
MRI at 3 Tesla. Second, follow-up data are missing, but
catheter ablation per se may have a significant impact on
Table 4 Cardiovascular risk profile of patients with or without cerebral microbleeds (CMB) according to available MRI data (n = 138)
CMB
No
(n = 108)
Yes
(n = 30)
p-value*
≥1 stroke risk factor** No 34 (31.5) 5 (16.7) 0.168
Yes 74 (68.5) 25 (83.3)
• Age; median (IQR) 59 (53–65) 64 (56–67) 0.098
Female sex; n (%) 37 (34.3) 4 (13.3) 0.040
Congestive heart failure; n (%) 9 (8.3) 2 (6.7) > 0.999
Arterial hypertension; n (%) 60 (55.6) 18 (60.0) 0.684
Diabetes mellitus; n (%) 9 (8.3) 3 (10.0) 0.769
Peripheral artery occlusive disease; n (%) 1 (0.9) 3 (10.0) 0.032
Coronary artery occlusive Disease; n (%) 18 (16.7) 6 (20.0) 0.786
Hyperlipoproteinemia; n (%) 51 (47.2) 17 (56.7) 0.412
Paroxysmal AF, n (%) 70 (58.8) 19 (59.4) > 0.999
INR > 3.0 prior to ablation, n (%) 16 (14.8) 3 (10.0) 0.765
Intake of phenprocoumon# 93 (86.1) 29 (96.6) 0.194
Intake of NOAK#, *** 15 (13.9) 1 (3.3)
* p-value calculated by chi2-test or Mann-Whitney U test, as appropriate. Multivariate analysis was calculated in a binary logistic regression model using backward
selection. ** According to CHA2DS2-VASc-score (“No” equals 0 in men and 1 in women, “Yes” equals ≥ 1 in men and ≥ 2 in women).
# at the time of study enrollment. ***
Non-Vitamin-K dependent oral anticoagulant
Table 5 Distribution of MRI-detected CMB in AF patients with
and without stroke risk factors and without prior stroke
according to medical history (n = 30)
AF without stroke risk factors
Yes
(n = 5)
No
(n = 25)
Multiple CMB; n (%) 0 (0) 6 (24.0)
Left hemisphere; n (%) 3 (60.0) 11 (44.0)
Both hemispheres; n (%) 0 (0) 4 (16.0)
Strictly lobar; n (%) 5 (100.0) 18 (72.0)
Strictly deep; n (%) 0 (0) 3 (12.0)
Mixed (lobar and deep); n (%) 0 (0) 1 (4.0)
Infratentorial region; n (%) 0 (0) 4 (16.0)
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further MRI findings [32, 33]. Third, duration of oral
anticoagulation prior investigation may have differed in
our study patients with or without stroke risk factors
and may have an impact on the presence of
MRI-detected cerebral microbleeds [34]. Fourth, all
study patients had symptomatic AF and were scheduled
to undergo left atrial catheter ablation. Therefore, the
generalizability of our data is limited to certain extent
and further studies in AF patients without stroke risk
factors are needed to validate or findings. Finally, the
sample size is rather small, although this is obviously the
largest published sample up to date.
Conclusion
Our data indicate that MRI-detected silent ischemic
brain lesions are a frequent finding in patients scheduled
for ablation due to symptomatic AF. Of note, the preva-
lence of silent ischemic brain lesions was similar in AF
patients with or without further stroke risk factors, re-
spectively. While the MRI-detected burden of microan-
giopathic lesions was rather low in both cohorts, there
was a trend for a lower prevalence of cerebral micro-
bleeds in AF patients without stroke risk factors. Further
studies are warranted to validate our findings in AF pa-
tients scheduled for ablation or in AF patients per se.
Additional file
Additional file 1: Table S1. Online Supplement: Baseline characteristics
of 175 study patients according to study center. Description of data: This
table contains the baseline characteristics of 175 study patients according
to study center (Berlin, Linz and Bocholt). (DOCX 14 kb)
Abbreviations
AF: Atrial fibrillation; MRI: magnetic resonance imaging; WMH: white matter
hyperintensities
Acknowledgements
Not applicable.
Availability of data and material
Data sharing is not possible because we do not have a respective consent of
the participating study patients to share the data.
Funding
The MACPAF study was supported by funding from the Federal Ministry of
Education and Research via the Competence Net Stroke and the Center for
Stroke Research Berlin (01 EO 0801). The present multicenter study was
investigator-initiated and not funded by an organization or institution. Sev-
eral study investigators (JH, JS, PUH, JBF, KGH) were employed (over a period
of time) by the Center for Stroke Research Berlin. None of the funding bodies
had any impact on the design of the study and collection, analysis, and inter-
pretation of data and the writing the manuscript.
This publication was funded by the German Research Foundation (DFG) and
the University of Wuerzburg in the funding programme Open Access
Publishing.
Authors’ contributions
All authors have read and approved the manuscript. JH and JS have made
substantial contributions to data acquisition, analysis and interpretation of
data and drafted the manuscript. MM, RH, HP, MW, AS and JBF made
substantial contributions to data acquisition and revised the manuscript
critically for important intellectual content. PK revised the manuscript
critically for important intellectual content. PUH has made substantial
contributions to analysis and interpretation of data and revised the
manuscript critically for important intellectual content. KGH has made
substantial contributions to conception and design, analysis and
interpretation of data and drafted the manuscript.
Ethics approval and consent to participate
The present data pooling has been approved by the Ethics Committee of
the Charité – Universitätsmedizin Berlin, Germany (EA4/087/08). Furthermore,
each individual study was approved by the local Ethics Committee before
(Ethics Committee Witten/Herdecke, Germany (114/2016); Ethics Committee
of the Elisabethinen University Teaching Hospital Linz, Austria (K-103-16)). All
study patients gave written informed consent.
Consent for publication
Not applicable.
Competing interests
JH, JS, MM, RH, AS, PK, HP and MW have nothing to declare. JBF has received
consulting, lecture, and advisory board fees from BioClinica, Cerevast, Artemida,
Brainomix, and Lundbeck. PUH reports research grants from Charité–
Universitätsmedizin Berlin (within MonDAFIS, supported by an unrestricted
research grant to the Charité from Bayer), University Göttingen (within FIND-
AFrandomized, supported by an unrestricted research grant to the University Göt-
tingen from Boehringer-Ingelheim), and University Hospital Heidelberg (within
RASUNOA-prime, supported by an unrestricted research grant to the University
Hospital Heidelberg from Bayer HealthCare, BMS, Boehringer-Ingelheim, Daiichi
Sankyo), outside submitted work. KGH received lecture honoraria from Bayer
HealthCare, Sanofi-Aventis, Pfizer, Bristol-Myers Squibb, Boehringer Ingelheim,
Daiichi Sankyo, Biotronik, W. L. Gore & Associates; honoraria for consulting from
Edwards Lifesciences, Bayer HealthCare, Pfizer, Daiichi Sankyo, Boehringer Ingel-
heim, EIP Pharma and Medtronic as well as research grants from Bayer HealthCare
and Sanofi-Aventis.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Department of Neurology, Charité - Universitätsmedizin Berlin, Berlin,
Germany. 2Center for Stroke Research Berlin, Charité - Universitätsmedizin
Berlin, Berlin, Germany. 3Department of Cardiology, Ordensklinikum Linz
Elisabethinen, Linz, Austria. 4Department of Cardiology and
Electrophysiology, St. Agnes-Hospital Bocholt, Bocholt, Germany.
5Department of Cardiology, Sana Clinic Lichtenberg, Berlin, Germany.
6Institute of Cardiovascular Sciences, University of Birmingham, Birmingham,
UK. 7Witten/Herdecke University, School of Medicine, Witten, Germany.
8Institute of Clinical Epidemiology and Biometry, University of Würzburg,
Würzburg, Germany. 9Clinical Trial Center Würzburg, University Hospital
Würzburg, Würzburg, Germany. 10Comprehensive Heart Failure Center,
University of Würzburg, Würzburg, Germany. 11Department of Neurology,
Universitätsklinikum Würzburg, Josef-Schneider-Str. 11 97080, Würzburg,
Germany.
Received: 23 July 2018 Accepted: 27 February 2019
References
1. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016
ESC guidelines for the management of atrial fibrillation developed in
collaboration with EACTS. Eur Heart J. 2016;37:2893–962. https://doi.org/10.
1093/eurheartj/ehw210.
2. Weijs B, Crijns HJGM. Lone or idiopathic atrial fibrillation, messenger of
misery in sight. Int J Cardiol. 2014;177:734–5. https://doi.org/10.1016/j.ijcard.
2014.09.181.
3. Camm AJ, Lip GYH, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al.
2012 focused update of the ESC guidelines for the management of atrial
fibrillation: an update of the 2010 ESC guidelines for the management of
Herm et al. BMC Cardiovascular Disorders           (2019) 19:58 Page 7 of 8
atrial fibrillation. Europace. 2012;14:1385–413. https://doi.org/10.1093/
europace/eus305.
4. Potpara TS, Stankovic GR, Beleslin BD, Polovina MM, Marinkovic JM, Ostojic MC,
et al. A 12-year follow-up study of patients with newly diagnosed lone atrial
fibrillation. Chest. 2012;141:339–47. https://doi.org/10.1378/chest.11-0340.
5. King JB, Azadani PN, Suksaranjit P, Bress AP, Witt DM, Han FT, et al. Left
atrial fibrosis and risk of cerebrovascular and cardiovascular events in
patients with atrial fibrillation. J Am Coll Cardiol. 2017;70:1311–21. https://
doi.org/10.1016/j.jacc.2017.07.758.
6. Mahnkopf C, Badger TJ, Burgon NS, Daccarett M, Haslam TS, Badger CT, et
al. Evaluation of the left atrial substrate in patients with lone atrial fibrillation
using delayed-enhanced MRI: implications for disease progression and
response to catheter ablation. Hear Rhythm. 2010;7:1475–81. https://doi.org/
10.1016/j.hrthm.2010.06.030.
7. Bisbal F, Gómez-Pulido F, Cabanas-Grandío P, Akoum N, Calvo M, Andreu D,
et al. Left atrial geometry improves risk prediction of thromboembolic
events in patients with atrial fibrillation. J Cardiovasc Electrophysiol. 2016;27:
804–10. https://doi.org/10.1111/jce.12978.
8. Gupta A, Giambrone AE, Gialdini G, Finn C, Delgado D, Gutierrez J, et al.
Silent brain infarction and risk of future stroke. Stroke. 2016;47:STROKEAHA.
115.011889. https://doi.org/10.1161/STROKEAHA.115.011889.
9. Haeusler KG, Wilson D, Fiebach JB, Kirchhof P, Werring DJ. Brain MRI to
personalise atrial fibrillation therapy: current evidence and perspectives.
Heart. 2014;100:1408–13. https://doi.org/10.1136/heartjnl-2013-305151.
10. Debette S, Markus HS. The clinical importance of white matter
hyperintensities on brain magnetic resonance imaging: systematic review
and meta-analysis. BMJ. 2010;341:c3666 https://www.ncbi.nlm.nih.gov/
pubmed/20660506. Accessed 23 Oct 2011.
11. Vermeer SE, Longstreth WT, Koudstaal PJ. Silent brain infarcts: a systematic
review. Lancet Neurol. 2007;6:611–9. https://doi.org/10.1016/S1474-
4422(07)70170-9.
12. Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical
characteristics to therapeutic challenges. Lancet Neurol. 2010;9:689–701.
https://doi.org/10.1016/S1474-4422(10)70104-6.
13. Mayasi Y, Helenius J, McManus DD, Goddeau RP, Jun-O’Connell AH, Moonis
M, et al. Atrial fibrillation is associated with anterior predominant white
matter lesions in patients presenting with embolic stroke. J Neurol
Neurosurg Psychiatry. 2017:jnnp–2016-315457. https://doi.org/10.1136/jnnp-
2016-315457.
14. Charidimou A, Kakar P, Fox Z, Werring DJ. Cerebral microbleeds and
recurrent stroke risk: systematic review and meta-analysis of prospective
ischemic stroke and transient ischemic attack cohorts. Stroke. 2013;44:995–
1001. https://doi.org/10.1161/STROKEAHA.111.000038.
15. Wilson D, Charidimou A, Ambler G, Fox ZV, Gregoire S, Rayson P, et al.
Recurrent stroke risk and cerebral microbleed burden in ischemic stroke
and TIA. Neurology. 2016;87:1501–10. https://doi.org/10.1212/WNL.
0000000000003183.
16. Haeusler KG, Koch L, Herm J, Kopp UA, Heuschmann P, Endres M, et al. 3
tesla MRI-detected brain lesions after pulmonary vein isolation for atrial
fibrillation: results of the MACPAF study. J Cardiovasc Electrophysiol. 2013;
24:14–21. https://doi.org/10.1111/j.1540-8167.2012.02420.x.
17. Martinek M, Sigmund E, Lemes C, Derndorfer M, Aichinger J, Winter S, et al.
Asymptomatic cerebral lesions during pulmonary vein isolation under
uninterrupted oral anticoagulation. Europace. 2013;15:325–31. https://doi.
org/10.1093/europace/eus329.
18. Kou S, Caballero L, Dulgheru R, Voilliot D, De Sousa C, Kacharava G, et al.
Echocardiographic reference ranges for normal cardiac chamber size: results
from the NORRE study. Eur Hear J Cardiovasc Imaging. 2014;15:680–90.
https://doi.org/10.1093/ehjci/jet284.
19. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al.
Recommendations for cardiac chamber quantification by echocardiography
in adults: an update from the American Society of Echocardiography and
the European Association of Cardiovascular Imaging. J Am Soc
Echocardiogr. 2015;28:1–39.e14. https://doi.org/10.1016/j.echo.2014.10.003.
20. Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal
abnormalities at 1.5 T in Alzheimer’s dementia and normal aging. AJR Am J
Roentgenol. 1987;149:351–6. https://doi.org/10.2214/ajr.149.2.351.
21. Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, et al.
Neuroimaging standards for research into small vessel disease and its
contribution to ageing and neurodegeneration. Lancet Neurol. 2013;12:822–
38. https://doi.org/10.1016/S1474-4422(13)70124-8.
22. Haeusler KG, Herm J, Kunze C, Krüll M, Brechtel L, Lock J, et al. Rate of
cardiac arrhythmias and silent brain lesions in experienced marathon
runners: rationale, design and baseline data of the Berlin beat of running
study. BMC Cardiovasc Disord. 2012;12:69. https://doi.org/10.1186/1471-
2261-12-69.
23. Cha M-J, Park HE, Lee M-H, Cho Y, Choi E-K, Oh S. Prevalence of and risk
factors for silent ischemic stroke in patients with atrial fibrillation as
determined by brain magnetic resonance imaging. Am J Cardiol. 2014;113:
655–61. https://doi.org/10.1016/j.amjcard.2013.11.011.
24. Kalantarian S, Ay H, Gollub RL, Lee H, Retzepi K, Mansour M, et al.
Association between atrial fibrillation and silent cerebral infarctions. Ann
Intern Med. 2014;161:650. https://doi.org/10.7326/M14-0538.
25. Sugioka K, Takagi M, Sakamoto S, Fujita S, Ito A, Iwata S, et al. Predictors of
silent brain infarction on magnetic resonance imaging in patients with
nonvalvular atrial fibrillation: a transesophageal echocardiographic study.
Am Heart J. 2015;169:783–90. https://doi.org/10.1016/j.ahj.2015.03.016.
26. Gaita F, Corsinovi L, Anselmino M, Raimondo C, Pianelli M, Toso E, et al.
Prevalence of silent cerebral ischemia in paroxysmal and persistent atrial
fibrillation and correlation with cognitive function. JACC. 2013;[Epub ahea.
https://doi.org/10.1016/j.jacc.2013.05.074.
27. Wieczorek J, Mizia-Stec K, Lasek-Bal A, Wieczorek P, Hoffmann A, Nowak S,
et al. CHA2DS2-Vasc score, age and body mass index as the main risk
factors of hyperintense brain lesions in asymptomatic patients with
paroxysmal non-valvular atrial fibrillation. Int J Cardiol. 2016;215:476–81.
https://doi.org/10.1016/j.ijcard.2016.04.094.
28. Charidimou A, Boulouis G, Shams S, Calvet D, Shoamanesh A. International
META-MICROBLEEDS initiative. Intracerebral haemorrhage risk in
microbleed-positive ischaemic stroke patients with atrial fibrillation:
preliminary META-analysis of cohorts and anticoagulation decision schema.
J Neurol Sci. 2017;378:102–9. https://doi.org/10.1016/j.jns.2017.04.042.
29. Karayiannis C, Soufan C, Chandra RV, Phan TG, Wong K, Singhal S, et al.
Prevalence of brain MRI markers of hemorrhagic risk in patients with stroke
and atrial fibrillation. Front Neurol. 2016;7:151. https://doi.org/10.3389/fneur.
2016.00151.
30. Charidimou A, Inamura S, Nomura T, Kanno A, Kim SN, Imaizumi T. Cerebral
microbleeds and white matter hyperintensities in cardioembolic stroke
patients due to atrial fibrillation: single-Centre longitudinal study. J Neurol
Sci. 2016;369:263–7. https://doi.org/10.1016/j.jns.2016.08.050.
31. Benameur K, Bykowski JL, Luby M, Warach S, Latour LL. Higher prevalence
of cortical lesions observed in patients with acute stroke using high-
resolution diffusion-weighted imaging. Am J Neuroradiol. 2006;27:1987–9
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747333/. Accessed 16 Aug
2011.
32. Haeusler KG, Kirchhof P, Endres M. Left atrial catheter ablation and ischemic
stroke. Stroke. 2012;43:265–70. https://doi.org/10.1161/STROKEAHA.111.
627067.
33. Herm J, Fiebach JB, Koch L, Kopp UA, Kunze C, Wollboldt C, et al.
Neuropsychological effects of MRI-detected brain lesions after left atrial
catheter ablation for atrial fibrillation: long-term results of the MACPAF
study. Circ Arrhythm Electrophysiol. 2013;6:843–50. https://doi.org/10.1161/
CIRCEP.113.000174.
34. Saito T, Kawamura Y, Sato N, Kano K, Takahashi K, Asanome A, et al. Non-
vitamin K antagonist Oral anticoagulants do not increase cerebral
microbleeds. J Stroke Cerebrovasc Dis. 2015;24:1373–7. https://doi.org/10.
1016/j.jstrokecerebrovasdis.2015.02.018.
Herm et al. BMC Cardiovascular Disorders           (2019) 19:58 Page 8 of 8
